Swiss drug maker Novartis AG said its experimental meningitis vaccine performed well in a large clinical trial and that the company expects to file for regulatory approval in the U.S. and Europe this year.
Novartis said the vaccine, called Menveo, helped trigger a strong immune response in a greater percentage of adolescents against several types of meningitis bacteria than did the currently used ...
Email
Printer Friendly
Order Reprints
